Impact of solid state properties on developability assessment of drug candidates

被引:322
作者
Huang, LF
Tong, WQ
机构
[1] Novartis Pharmaceut, Pharmaceut & Analyt Dev, E Hanover, NJ 07936 USA
[2] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA
关键词
developability; solubility; stability; solid state properties; polyinorphs; pseudopolymorphs; solvates; salts; crystal form screening;
D O I
10.1016/j.addr.2003.10.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Solid state properties including polymorphism, solvate and salt formation can have a profound impact on two of the most important properties that are essential to the successful development of drug candidates: solubility and stability. To enable meaningful evaluations of drug candidates for their development risks, often referred to as developability, and provide input to the molecular design regarding the "drug-like" properties, one must take into account the impact of solid state properties on solubility and stability. This review examines the importance of solid state properties and their relationship to developability criteria. Phase appropriate characterization strategies and appropriate salt and crystal form screening and selection processes are discussed. These strategies and processes should balance the need for speed and throughput of modem discovery with the quality of data essential to the adequate developability assessment. Specific examples are given to illustrate the importance of understanding the solid state properties and their impact on developability. (C) 2003 Published by Elsevier B.V.
引用
收藏
页码:321 / 334
页数:14
相关论文
共 45 条
[1]   EFFECT OF POLYMORPHISM ON ABSORPTION OF CHLORAMPHENICOL FROM CHLORAMPHENICOL PALMITATE [J].
AGUIAR, AJ ;
KRC, J ;
KINKEL, AW ;
SAMYN, JC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1967, 56 (07) :847-+
[2]  
Almarsson O., 2003, NOVEL APPROACHES ISS, P21
[3]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[4]  
ANDO HY, 2000, REMINGTON SCI PRACTI, P700
[5]  
[Anonymous], 1995, ENCY PHARM TECHNOLOG
[6]  
AVEEF A, 2001, PHARM OPTIMIZATION D, P305
[7]   Salt selection and optimisation procedures for pharmaceutical new chemical entities [J].
Bastin, RJ ;
Bowker, MJ ;
Slater, BJ .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (05) :427-435
[8]  
Bernstein J, 1999, ANGEW CHEM INT EDIT, V38, P3440, DOI 10.1002/(SICI)1521-3773(19991203)38:23<3440::AID-ANIE3440>3.0.CO
[9]  
2-#
[10]   A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates [J].
Bevan, CD ;
Lloyd, RS .
ANALYTICAL CHEMISTRY, 2000, 72 (08) :1781-1787